Immuneering Corporation

Immuneering Corporation

IMRX · Nasdaq

Immuneering Corporation (IMRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Immuneering Corporation in 2026. The next earnings report is expected on November 5, 2026.

Earnings calendar

Next earnings date

05 Nov 2026

In 76 days

EPS estimate

-0.31

Revenue estimate

0

Past earnings

06 Aug 2026
EPS actual
-0.27 (-2.2%)
estimate -0.26
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
15 May 2026
EPS actual
-0.21 (+16.7%)
estimate -0.25
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 Mar 2026
EPS actual
-0.18 (+42.4%)
estimate -0.31
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.38 (+2.1%)
estimate -0.39
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Immuneering Corporation missed consensus estimates on EPS, reporting a loss of $0.27 per share versus an estimated loss of $0.2643, while revenue met expectations at $0. In the prior report, EPS came in ahead of expectations and revenue also met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Benjamin J. Zeskind
Employees
54
IPO date
30 Jul 2021
ISIN
US45254E1073
Website
immuneering.com

Frequently asked questions

When does Immuneering Corporation (IMRX) next report earnings?

Immuneering Corporation (IMRX) is scheduled to report earnings on November 5, 2026.

What was Immuneering Corporation's most recent earnings date?

Immuneering Corporation (IMRX) last reported earnings on August 6, 2026.

Where is Immuneering Corporation stock listed?

Immuneering Corporation (IMRX) is listed on Nasdaq.